A Relative Strength Rating upgrade for Stifel Financial shows improving technical performance. Will it continue?

The potential approval of Vertex’s IgAN therapy povetacicept in 2026 comes amid launch headwinds for the company’s non-opioid ...

Trevi Therapeutics, Inc. , a clinical-stage biopharmaceutical company developing the investigational therapy Haduviotm (oral nalbuphine ER) for the treatment of chronic cough in patients with ...

Seaport Therapeutics management team will present at Stifel 2025 Healthcare Conference on November 11 at 10:00AM EST.

2. Mergers and acquisitions are picking up: So far this year, buyouts have boosted several biotech stocks. Some standouts: Regulus Therapeutics went up 120%; 89bio went up 85%; Chimerix gained 69% and ...

A. O. Smith Corporation (NYSE: AOS) is included among the 13 Best Consistent Dividend Stocks to Buy Now.

With the 2025-26 season on the horizon, Copper Mountain is gearing up for a season full of fresh turns, events and ...

The Base Shelf Prospectus is accessible, and the Prospectus Supplement will be accessible within two business days, through SEDAR+ /NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR ...

Solventum (NYSE: SOLV) announced today its executives will participate in a fireside chat at the Stifel Healthcare Conference ...

Stifel Nicolaus analyst Matthew Smith, CFA maintained a Buy rating on Altria Group today and set a price target of $72.00. The company’s shares opened today at $57.16. Elevate Y ...

Fintel reports that on October 31, 2025, Stifel maintained coverage of S&P Global (NYSE:SPGI) with a Buy recommendation.

Stifel CEO Ron Kruszewski wants to be clear: His company isn’t for sale. Kruszewski told employees just that in a memo on ...